GlassScriptPhysician profile
Kimberley A Mangus
NPI 1275075848
$4,903.24
in general payments reported to CMS, 2019-2025
28 companies · $1,555 in 2025
The $1,555 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $235 · 2023: $1,636 · 2024: $1,357 · 2025: $1,555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,515 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,515.42 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $665.72 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.47 | 2021-2025 | Jardiance |
| Abbott Laboratories | $407.28 | 2023-2024 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $367.42 | 2022-2025 | Farxiga, Brilinta |
| Novo Nordisk INC | $343.34 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $318.62 | 2023-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $305.98 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $278.16 | 2022-2025 | |
| Scpharmaceuticals INC. | $224.44 | 2023-2025 | |
| Bridgebio Pharma, INC. | $175.26 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $158.41 | 2022-2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $157.23 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $149.14 | 2022-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $105.79 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.33 | 2023-2025 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $97.42 | 2023-2024 | Inpefa |
| Lantheus Medical Imaging, INC. | $81.27 | 2023-2025 | Definity |
| Boston Scientific Corporation | $71.21 | 2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Esperion Therapeutics, INC. | $70.50 | 2025 | Nexletol |
| Irhythm Technologies, INC. | $66.90 | 2022-2023 | Zio Xt Patch |
| Lilly USA, LLC | $48.72 | 2025 | Zepbound, Mounjaro |
| Philips North America LLC | $41.93 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Bayer Healthcare Pharmaceuticals INC. | $36.62 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $35.86 | 2023-2024 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $26.80 | 2025 | Amvuttra |
| Ge Healthcare | $17.37 | 2025 | |
| Kestra Medical Technology Services, INC. | $15.06 | 2023 | Assure Wcd |
| Medicomp INC | $13.99 | 2024 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberley Mangus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.